FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1908-1909 October 28, 2004 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Lipshultz, S. E. PubMed Citation

To the Editor: Lipshultz et al. (July 8 issue)¹ show that dexrazoxane reduces the cardiac toxicity of doxorubicin without compromising the antileukemic effects. Although dexrazoxane is a promising cardioprotective agent, physicians might suspect that it reduces both the adverse and the beneficial effects of doxorubicin. Since the rate of complete remission is affected by the characteristics of the patient, monitoring of event-free survival is not sufficient to show that dexrazoxane does not reduce the antileukemic effects of doxorubicin. To show that dexrazoxane specifically affects the myocardium, the rates of noncardiac adverse events, such as myelosuppression and mucositis, would be helpful.

. . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.